RxDoctor Payments Data

Menhel Kinno

Cardiovascular Disease · Chicago, ILNPI 1477862001

Payments from drug & device makers

$24,771in general payments, 2019–2025

Across 29 payments — averaging $854.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akcea Therapeutics, Inc.$16K
  • Pfizer$7K
  • Abbott$1K
  • Cleerly, Inc.$186
  • Heartflow, Inc.$171
  • Bracco Diagnostics Inc.$144
  • plus $157 from 5 others

What the payments were for

  • Consulting fees$3,59334%
  • Speaking & faculty fees$4,62544%
  • Travel & lodging$7017%
  • Food & beverage$1,09210%
  • Education$4204%

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,771 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$95,503
Medicare patients
727
Services billed
1,235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis33$931,749
EliquisApixaban124$190,376
EntrestoSacubitril/Valsartan46$52,268
JardianceEmpagliflozin35$41,345
XareltoRivaroxaban22$27,233
Praluent PenAlirocumab25$22,052
Repatha SureclickEvolocumab16$11,780
VascepaIcosapent Ethyl11$5,306
Atorvastatin Calcium360$4,522
Metoprolol Succinate194$3,259
Nifedipine ErNifedipine41$1,821
Bumetanide43$1,742
Rosuvastatin Calcium129$1,705
Losartan Potassium165$1,539
Ezetimibe54$1,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$7,144$1,122,124157 claims
NovartisEntresto$19$52,26846 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →